Clinical trial • Phase I • Other
BI 3814916 for Healthy volunteers
Phase I trial of BI 3814916 for Healthy volunteers. 136 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 28-01-2026
- First CTIS Authorization Date
- 13-03-2026
Trial design
Phase I trial across 1 site in Belgium.
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 136
Recruitment
- Planned Sample Size
- 136
- Recruitment Window Months
- 13
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 136
Belgium
- Earliest CTIS Part Ii Submission Date
- 27-02-2026
- Latest Decision Or Authorization Date
- 11-05-2026
- Processing Time Days
- 73
- Number Of Sites
- 1
- Number Of Participants
- 136
Sites
- Site Name
- SGS Belgium
- Department Name
- Clinical Pharmacology Unit
- Contact Person Name
- Frederic Vanhoutte
- Contact Person Email
- frederic.vanhoutte@sgs.com
Sponsor
Primary sponsor
- Full Name
- Boehringer Ingelheim International GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- BI 3814916
Related trials
Other published trials that may interest you.